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consinImpending Challenges in the Hematopoietic Stem Cell
Transplantation Physician Workforce
James L. Gajewski,1 C. Frederick LeMaistre,2 Samuel M. Silver,3 Michael C. Lill,4
George B. Selby,5 Mary M. Horowitz,6 J. Douglas Rizzo,7 Helen E. Heslop,8 Claudio Anasetti,9
Richard T. Maziarz1With increasing use of high dose chemotherapy with autologous and allogeneic transplants the need for the
transplant physician workforce requires reassessment. The types of transplants and patients are also shifting
toward transplants being done in patients with more comorbidities and more commonly these types of pa-
tients require more work effort per patient from the transplant physician. Additionally, HSCT survivors of-
ten require ongoing care at the transplant center due to the inability of the primary care workforce or the
hematology/oncology workforce to absorb caring for post complex post transplant patients. The adult
transplant workforce has had very few physicians join under age 40. Nearly 50% of adult transplant physicians
are over age 50 whereas only 28% of pediatric transplant physicians are over age 50. By 2020, it is projected
that we will need 1,264 new adult transplant physicians and 94 pediatric transplant physicians. Training time
for a physician is approximately 15 years. The capping of both medical school slots and residency slots since
the early ‘80s is now having a very big impact on supply, but other factors are also affecting supplies such as
generational differences, lifestyle expectations, and the change of the medical workforce from being mostly
men. Workforce shortages are being reported for many specialities. Workforce problems are also present
for nurses, pharmacists and medical technologists. So increasing use of general internists and mid-level pro-
viders may not exist as a solution. Transplant physicians must be actively engaged in the medical education
process to show young medical students and residents who are not committed to another sub specialty ca-
reer the excitement and challenges of a career in bone marrow transplantation, so that our field will have
providers for the future.
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Since the first report of allogeneic marrow trans-
plantation in humans more than 50 years ago, the ap-
plications have evolved from developmental therapies
in a select group of desperate patients to standard ther-
apies for patients with a wide variety of indications [1].
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cell transplantation (HSCT) has been limited by
patient selection, the toxicity of the procedure, the
availability of donors, and the significant expense of
building and staffing facilities to deliver these complex
therapies. As these limitations have been at least par-
tially overcome, the number of patients treated with
HSCT has continually increased [1]. It now appears
that a lagging physician workforce—specifically
a lack of specialty-trained hematologists and medical
oncologists with a focused interest in cellular ther-
apy—may represent a new barrier to the expansion of
HSCT and other cellular therapies [3,4].COMPLEXITY IN STUDYING PHYSICIAN
WORKFORCE NEEDS BASED ON
TRANSPLANTATION USAGE
Initially, HSCT was limited to younger patients
suffering from a limited number of hematologic, im-
mune, and genetic diseases, often in relatively ad-
vanced stages. Transplantation therapies were further
restricted by the need to collect hematopoietic stem
cells from the marrow of either matched histocompat-
ible family members or the patients themselves.
The use of high-dose chemotherapy and autolo-
gous stem cell transplantation was significantly en-
hanced by the use of hematopoietic progenitors
harvested from the peripheral blood, commonly
referred to as peripheral blood stem cells (PBSCs).
The ability to collect large numbers of PBSCs facili-
tated more rapid engraftment and, in conjunction
with other advances in supportive care, decreased
treatment-related morbidity and mortality [5]. These
improvements catalyzed the evolution of autologous
HSCT as a standard of care and its integration into
planned treatment algorithms for several diseases. In
addition, for patients with some diseases (eg, multiple
myeloma), HSCT has been used to improve disease
control or progression-free survival, rather than exclu-
sively as a curative treatmentmodality, further expand-
ing its applicability to new patient populations [6].
Autologous HSCT also is considered a standard treat-
ment for elderly patients, who are at the greatest risk
for developing malignancies [7]. These expanded ap-
plications for autologous HSCT, coupled with
improvements in survival from cardiac disease as a re-
sult of improved treatment and prevention and the
changing age demographics in the United States,
Europe, and Japan, are likely to significantly increase
the need for autologous HSCT over the next decade.
Conversely, the development of novel therapeutics
may result in a decrease in utilization of HSCT in spe-
cific disease states that currently represent common
indications for autologous transplantation (eg, multi-
ple myeloma).Expanded applications have not been limited to
autologous HSCT; in fact, expansion of HSCT appli-
cations may be even more accentuated with allogeneic
HSCT. For example, improvements in supportive care
and other innovations that reduce toxicity have
expanded the number of patients eligible for allogeneic
HSCT [1,7]. Clinical research studies have addressed
and will continue to address other major obstacles to
allogeneic HSCT. Well-designed research trials have
demonstrated the ability to use less-intense, upfront
conditioning regimens that give older and more infirm
recipients the opportunity to receive a donor immune
system with the goal of eradicating their cancer [8].
The identification of strong graft-versus-cancer effects
in various malignancies has expanded the number of
diseases that potentially can be treated with allogeneic
HSCT. Advances in the prevention and treatment of
graft-versus-host disease (GVHD), as well as the iden-
tification and expansion of treatments for opportunis-
tic infections, have increased the number of patients
considered for transplantation [9]. In addition, the
ability to reproducibly and rapidly perform molecular
DNA sequencing for human leukocyte antigen (HLA)
typing has allowed the selection of donors for unre-
lated transplants with a diminished risk of advanced
GVHD [10]. This technology, coupled with the rapid
expansion of the National Marrow Donor Program
(NMDP) to 11million volunteer donors, has made un-
related donor transplants an option for far greater
numbers of patients. Furthermore, recent advances in
the use of umbilical cord transplantation coupled
with the expansion of umbilical cord banks have
extended allogeneic transplantation to those lacking
unrelated donors [11]. As a result, patients with co-
morbid conditions who previously would have been
denied transplantation are now eligible for HSCT.
Patients in their seventh and even eighth decade are
now being treated with allogeneic HSCT [7], and
some investigators no longer consider age a barrier
to treatment. Today, a more accurate assessment of
clinical comorbidities appears to have a greater influ-
ence than age on HSCT outcomes [12].
The cumulative effect of recent advances in
HSCT has significantly increased the number of pa-
tients being referred to and cared for in transplanta-
tion centers. Most of this growth has been in
allogeneic HSCT, primarily for patients receiving
unrelated cord blood and adult donor hematopoietic
stem cells [13]. This expanded patient load is requir-
ing many centers to provide more pretransplantation
malignancy care, transplantation procedures, and so-
phisticated posttransplantation management. The
greatest increase in patient volume is occurring in
older patients and in those receiving allogeneic trans-
plantations from alternative donors—the most com-
plicated patients. This means that when evaluating
physician workforce needs, the expanded patient
Table 1. Survival of Unrelated HSCT Recipients at US
Transplantation Centers [27]
Report Year Period
One-Year Survival
Rate, %
2003 1996-2001 42.2
2006 2000-2004 48.8
2007 2001-2005 51.5
Biol Blood Marrow Transplant 15:1493-1501, 2009 1495Challenges in the HSCT Physician Workforceload cannot be viewed simply as an incremental
growth in patient volume.
In addition to increased medical needs, psycholog-
ical, social, and caregiver needs also may further
increase workload demands on the specialty practi-
tioner. Finally, the success of HSCT has established
a need for long-term care programs to manage trans-
plantation survivors with chronic diseases, including
not only chronic GVHD, but also acquired secondary
hepatic, pulmonary, cardiac, and renal disorders, as
well as preexisting comorbidities. Along with facing
problems associated with the active care of patients
during transplantation, HSCT physicians also bear
some responsibility for long-term survivors. Many of
these survivors cannot be easily reintegrated into a pri-
mary care physician’s practice or a medical oncolo-
gist’s practice. With the increasing numbers of
transplantations and survivorship percentages has
come a significant growth in patient volume. The esti-
mated number of HSCTs performed annually in the
United States has increased from 15,000 in 1999 to
18,600 in 2006. Similar trends are seen worldwide
[14]. Approximately 40% of those undergoing
HSCT become long-term survivors, suggesting that
a substantial and increasing number of survivors are re-
quiring care for survivorship issues following HSCT
on an annual basis. For many patients with GVHD
or whose immunodeficiency state exacerbates general
medical management, the HSCT physician becomes
their primary care physician, and the transplantation
clinic becomes their medical home (D. Rizzo and M.
Horowitz, personal communication, June 2009).
Although registry information from the CIBMTR
and surveys from the European Group for Blood and
Marrow Transplantation provide some insight into
transplantation therapy utilization, forecasting future
needs remains complex [15]. While it is likely that
advances in HSCT will lead to improved outcomes
and an even wider use of transplantation therapies, it
also is likely that advances in identification of cancer-
specific molecular pathways and subsequent pharma-
ceutical innovations may replace HSCT for some
diseases. The use of tyrosine kinase inhibitors in the
treatment of chronic myelogenous leukemia is a nota-
ble example [16].
The impact of access (or lack thereof) to care on
the number of patients offered HSCT has historically
been difficult to assess. Data from the European
Group for Blood andMarrowTransplantation suggest
that transplantation rates are higher in countries with
greater gross national income or health care expendi-
tures per capita [17]. If uninsured Americans (11% of
children and 15% of nonelderly adults) had full access
to health care, then HSCT rates may increase [18-20].
Economic systems influence transplantation access
differently. In countries with high tariffs (or restric-
tions?) on imported novel drugs, access to new drugsis limited to wealthier families; allogeneic transplanta-
tion remains the preferred treatment option for pa-
tients with chronic myelogenous leukemia [21]. With
a reduction in treatment-related toxicities, HSCT
has become an option for various diseases, particularly
in pediatric patients, not previously considered for this
type of treatment. Clearly, assessing health care needs
for the future is problematic and fraught with inaccur-
acy if done with straight-line predictions based on
population growth and demographic shifts.
A recent CIBMTR publication suggests that the
lifetime probability of undergoing HSCT is much
higher than previously thought [22]. The CIBMTR
considered several scenarios using the following as-
sumptions: (1) no change in current indications for au-
tologous and allogeneic HSCT, (2) universal donor
availability, and (3) broadened use of HSCT in hema-
tologic malignancies. The estimated lifetime probabil-
ity of undergoingHSCT ranged from 0.23% to 0.98%
depending on the scenario under consideration, and
was deemed to be greater with increasing donor avail-
ability and HSCT applicability. These transplantation
rates suggest that 17,000-32,000 HSCTs will be per-
formed annually in the United States. But these pre-
dictions did not account for the predicted expansion
of the US population by more than 50 million between
2000 and 2020 [1], nor did they fully account for the
expansion of the elderly population. The population
over age 85 years is one of the fastest-growing demo-
graphic groups in the United States [23,24].
Information from the NMDP demonstrates the
current unmet need for unrelated HSCTs. The
NMDP predicts that the number of transplantations
that they facilitate will increase from the current level
of 4,000 to 10,000 within the next 6 years [1], validat-
ing the concerns regarding increased workforce pres-
sures on transplantation facilities going forward [25].
The number of transplantations facilitated by the
NMDP has tripled over the last decade and is growing
by 12.5% annually (D. Confer, personal communica-
tion, June 2009). Whether or not this growth rate is
sustainable given current workforce and facility space
is unclear. According to the NMDP, as with other
HSCT patients, the greatest growth in unrelated do-
nor HSCT is for patients age 60 years and older with
preexisting comorbidities [26]. The eligibility of these
patients has contributed to an increase in both alloge-
neic and autologous transplantations for diseases that
Table 2. Age of BMT Physicians
Age
Range, Years
All BMT
Physicians, %
Adult BMT
Physicians, %
Pediatric BMT
Physicians, %
70-78 1.6 1.8 0
65-69 3.1 3.5 0
60-64 10.2 11.7 2.4
55-59 13.6 14.8 6.5
50-54 21.2 21.5 18.7
45-49 18.6 20.0 12.2
40-44 17.1 15.1 28.5
34-39 14.6 11.6 31.7
All ages 100 100 100
Data derived, with permission (R. Krawisz, personal communication,
June 2009), from the ASBMT membership records.
Table 3. Estimated Supply and Demand of BMT Physicians
Adult BMT
Physicians, n
Pediatric BMT
Physicians, n
All BMT
Physicians, n
BMT physician requirements
in 2020
1991 235 2226
Current supply 959 156 1115
Projected retirements 232 15 247
New BMT physicians needed 1264 94 1358
Data derived, with permission (R. Krawisz, personal communication,
June 2009), from the ASBMT membership records.
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dysplastic syndromes, acute myelogenous leukemia,
and non-Hodgkin lymphoma [26].
Despite these challenges, 1-year survival rates for
unrelated allogeneic HSCT recipients have increased
to. 50% over the last 10 years [26]. These successes
create challenges for the long-term care of these com-
plex patients. Table 1 shows that NMDP transplanta-
tion outcomes have improved by nearly 10 percentage
points in just 4 years [27].HSCT PHYSICIANWORKFORCE
PROJECTIONS
No formal attempts have been made to establish
projections for the number of physicians needed to
perform the predicted increase in the number of
HSCTs. Moreover, a detailed description of the phy-
sician workforce performing transplantations is lack-
ing. Consequently, the American Society of Blood
and Marrow Transplantation (ASBMT) agreed to in-
vestigate this potential problem. The ASBMT is a na-
tional professional association that promotes
advancement of the field of blood and marrow trans-
plantation, of which its constituent members are active
both in clinical practice and research. In attempting to
analyze physician workforce requirements, given the
lack of a database truly identifying transplantation spe-
cialists, the ASBMT began with the assumption that
90% of physicians performing HSCTs in the United
States are ASBMT members. Table 2 presents the
age distribution of BMT physician members of the
ASBMT (R. Krawisz, personal communication, June
2009).
The difference in age distribution between pediat-
ric and adult transplantation physicians is striking,
with a much higher percentage of pediatric transplan-
tation physicians in younger age groups. One possible
explanation for this discrepancy is that pediatric hema-
tology/oncology practices are almost exclusively aca-
demic practices, whereas adult hematology/oncology
practices are primarily private practices. Graduates ofadult hematology/oncology fellowship programs are
lured by the higher compensation offered by private
practice compared with academic practice settings. A
similar effect is noted in enrollment to clinical trials.
Enrollment of pediatric patients with hematology/on-
cology diseases into clinical trials is higher than enroll-
ment of adult patients with hematology/oncology
diseases, in part because patients treated in academic
settings are more likely to be enrolled in clinical trials.
Most pediatric patients with hematology/oncology ill-
nesses are treated in academic centers [28]. The fact
that nearly 50% of adult transplantation physicians
are over age 50 has raised concerns about succession
planning in this specialty (Table 2). In contrast, 72%
of pediatric hematology/oncology physicians are un-
der age 50, with most in the early stages of their career.
The results of an ASBMTmembership survey also
provide insight into how physicians spend their time.
BMT physicians spend approximately 50% of their
time in clinical practice, 23% in clinical research,
and 15% in laboratory research, with the balance de-
voted to administrative or teaching duties. (R. Krawisz,
personal communication, June 2009)
Based on data from the ASBMT’s membership
roles, it is estimated that 959 adult and 156 pediatric
physicians, or a total of 1115 physicians, perform
HSCTs (Table 3) (R. Krawisz, personal communica-
tion, June 2009). To estimate physician workforce
needs for the year 2020, the following assumptions
were made: (1) Population-based growth projections
were adjusted for age, (2) the current transplantation
usage rates were not adjusted, and (3) projections to
predict greater numbers of unrelated donors or new
therapeutic uses of transplantation were not done.
With these assumptions, an estimated 2226 transplan-
tation physicians (1991 adult physicians and 235 pedi-
atric physicians) will be needed in the year 2020. This
calculation assumes that these physicians will have
similar clinical commitments and that the increase in
midlevel practitioners providing care will be propor-
tional. Furthermore, it can be assumed that almost
22% of the transplantation physician workforce will
have retired at age 65. With projected growth and re-
tirement rates, these data suggest the need for 1358
new physicians performing HSCTs just to meet the
current demand.
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Figure 1. Supply of physicians in the United States and other developed countries [29]. Data prepared by Association of American Medical Colleges
Center for Workforce Studies (E. Salsberg, personal communication, May 2009).
Table 4. Recent Reports of Physician Shortages by Specialty
Specialty Year Reported
Allergy and immunology 2000
Anesthesia 2003
Cardiology 2004
Child psychiatry 2006
Critical care workforce 2006
Dermatology 2004
Emergency medicine 2006
Endocrinology 2003
Family medicine 2006
General surgery 2008
Geriatric medicine 2007
Medical genetics 2004
Neurosurgery 2005
Oncology 2007
Pediatric subspecialty 2008
Psychiatry 2003
Public health 2007
Rheumatology 2007
Data from the Association of American Medical Colleges Center for
Workforce Studies (E. Salsberg, personal communication, May 2009).
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The ASBMT’s workforce projection is based on
several assumptions and is subject to limitations. If
the estimated number of US-based subspecialty physi-
cians needed to manage HSCT patients is real, then
the paucity of physicians available to fill this need is
of concern. At the very least, the government, the
health care community, and the patients served need
a better understanding of the HSCT physician
workforce.
In some respects, the issues facing the HSCT phy-
sician workforce reflect the larger physician workforce
issues in the United States. Both the Council on Grad-
uate Medical Education and the American Association
of Medical Colleges project a physician shortfall of
85,000-96,000 by 2020. Currently, the US ranks
13th in physicians per 100,000 people among devel-
oped countries (264 physicians/100,000 people) [29]
(Figure 1).
Physician demand is driven both by the growth of
the US population and by demographic shifts within
that population [30]. As stated previously, the US pop-
ulation is expected to increase by more than 50 million
between 2000 and 2020. As a result of the ‘‘baby
boomer’’ population surge, the ‘‘over-65’’ population
segment is expected to grow from 35 million in 2000
to 54 million in 2020; similar population surges are an-
ticipated in other countries [23]. Given that patients
over age 65 use more health care services and often re-
quire multispecialty care, the physician workforce
must expand at a more than proportional rate to
meet the demands on health care.Despite these demands, per capita enrollment in
medical schools has remained flat since 1980. The
American Association of Medical Colleges noted that
a 30% increase in medical school enrollment by the
year 2015 is needed to keep up with current population
growth [30]. Even if this goal is achieved, the enroll-
ment rate will be below that documented in 1980.
Barriers to increasedmedical school enrollment ex-
ist include a lack of available financial support and/or
scholarships, limited classroom/laboratory space, and
limited ambulatory and other hospital-based clinical
training sites [30]. US medical schools are funded
1498 Biol Blood Marrow Transplant 15:1493-1501, 2009J. L. Gajewski et al.primarily through state budgets. In the current eco-
nomic climate, expanding the number or capacity of ex-
isting medical schools will be difficult given the
tremendous pressure to reduce state spending and re-
duce or maintain expenditures on resource-intensive
projects. Thus, whether a 30% increase in US medical
school capacity is realistically achievable by 2015 is
unclear.
A true expansion of the physician workforce can
occur only with a coordinated and equal expansion of
graduate medical education slots required for comple-
tion of residency training. Reconsideration of the cur-
rent caps on graduate medical education slots in the
US is needed. Funding for graduate medical education
has been in jeopardy for years [30]. If funding for med-
ical schools is reduced significantly, then the essential
mission of teaching hospitals will be severely compro-
mised, because passing on teaching costs as a direct pa-
tient care expense is neither feasible nor realistic.
Funding for graduate-level medical education comes
primarily from the federal government and is placed
within the Medicare budget [30]. This budgeting
anomaly associated with an embattled entitlement pro-
gram creates pressure to eliminate Medicare funding
as a cost-saving measure; interestingly, some of the
dollars targeted for elimination include those used to
pay graduate-level medical school faculty.
Other factors are contributing to the physician
shortage as well. Many medical students graduate
from medical school with significant debt, often as
much as $100,000-$200,000 [31]. Several years of
low-income compensation during residency and fel-
lowship training follow. These financial realities are
contributing to the increasing difficulty in recruiting
talented college graduates into the medical field. Fur-
thermore, attrition from the medical field before re-
tirement age has been increasing, attributed in part
to the increased workload requirements [32,33] and
decreased reimbursement for services provided rela-
tive to other professions in our society [31]. As a conse-
quence, the primary care fields and many medical
specialties are experiencing shortages (Table 4) [4; E.
Salsberg, personal communication, May 2009].
For decades, one solution has been to recruit for-
eign-trained physicians to meet these shortages [30].
But recent changes in immigration policies are making
itmore difficult for foreignmedical school graduates to
enter the United States for both residency training and
new positions [34]. In addition, worldwide economic
development is increasing local health care needs. To-
day, Asian and European countries are more likely to
retain their medical school graduates [34].With recog-
nition that many of the younger members of the
ASBMT are international medical graduates, the pool
ofUS-trained physicians specializing inHSCTneeded
to replace those who retire and to accommodate grow-
ing demands may be even smaller than projected.Midlevel practitioners, while helpful, also are fac-
ing demographic challenges as they attempt to main-
tain their current workforce levels. The average age
of nurses in the US is almost 50 years [35]. Many
more opportunities are available for nurses beyond di-
rect patient care; for example, nurse practitioners are
drawn from this workforce pool. In addition, most
nurse practitioner training programs focus on outpa-
tient care rather than on inpatient acute care. Physician
assistants often seek training 10 years after completing
an initial undergraduate degree, and because the clin-
ical training program is only 2 years long, find it diffi-
cult to transition into supporting complex medical
patients without extensive on-the-job training. Phar-
macy and medical technology workforces are aging
as rapidly as the physician and nursing workforces,
which may further affect physician workload demands.
Other difficult-to-measure factors have unin-
tended influences on the ability to maintain an ade-
quate pool of specialty-trained physicians to meet the
needs of patients requiring HSCT. Resident training
programs in internal medicine and pediatrics are
focusing increasingly on ambulatory care, with an em-
phasis on single-organ system problem management
[36,37]. Inpatient training for internal medicine house
officers is being increasingly provided under the tute-
lage of a general internal medicine hospitalist rather
than from the supply of internal medicine subspecial-
ists. Using subspecialists as the teaching attending
has the additional benefit of integrating complex spe-
cialty medicine with ongoing active general medicine
problems requiring acute hospitalization. Hospital-
ist-led inpatient teaching often focuses attention solely
on the patient care issue requiring acute hospitaliza-
tion, leaving the management of other ongoing medi-
cal problems to individual specialty consultants in the
outpatient setting, with possible readmission under
a separate specialty service. Both of these trends influ-
ence the ability to train a cadre of internal medicine
graduates comfortable in managing patients with
multiorgan dysfunction or failure in complex inpatient
and outpatient milieus.
This change in focus increasingly results in leaving
the hospital management of cancer patients to the
hematology and medical oncology subspecialists,
whose training of fellows also has become increasingly
focused on ambulatory medicine. Cancer care must
now be delivered in conjunction with treatment of
other comorbid diseases, which may either complicate
cancer care or eliminate certain options from
consideration. Primary care physicians have not been
adequately trained to decipher optimal cancer treat-
ments in the context of a patient’s overall health para-
digm.HSCT training requires physicians to have good
basic internal medicine or pediatric skills, in addition
to a thorough understanding of transplantation and
the disease processes that it is used to treat.
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mographics of the US physician pool. Currently, US
medical school enrollment is almost 50% women
[38]. The increase in female physicians has produced
dramatic changes in practice patterns. Many women
choose to share professional duties with childbearing
and rearing [39]. As the current aging physician work-
force approaches retirement, a one-to-one replace-
ment of the clinical physician full-time equivalents
(FTEs) may not be possible.
The implementation of electronic medical records
and ordering, in response to the Institute ofMedicine’s
position statement on the need to decrease the number
and impact of patient care medical errors, has led to
even greater demands on physician time. These
responsibilities add to the non–face-to-face time bur-
den of physicians managing patients with multiple lab-
oratory abnormalities and multiple medications.
These systems may be helpful for patients with a single
problem, but often lead to information overload with
complex patients. HSCT physicians need to prioritize
face-to-face time with patients given the immediate
life-threatening aspects of the disease requiring trans-
plantation and potential treatment-related morbidity
of the transplantation procedure.
The natural response to all of these demands for
specialized medical care, recognizing the lack of an
available physician pool, has been to create a new
workforce. Specifically, the critical importance of the
‘‘mid-level providers’’ for our field has emerged, utiliz-
ing advanced-level nurse practitioners, physician assis-
tants, and clinical pharmacists [40]. In addition, more
clinical management is being diverted to generalists,
such as hospitalists. HSCT care providers are usually
good hospitalists. Most HSCT physicians prefer to
be the hospitalist. Should this continue? Different pro-
grams given staffing options may need to consider
alternatives. All of these workforce groups have grow-
ing supply problems; thus, this may prove to not be the
ultimate remedy. In addition, the issue of compensa-
tion for the co-management of complex patients by
hospitalists and BMT physicians has not been well ad-
dressed by the current payment system.
Another difficult-to-assess effect on the HSCT
physician workforce is the economics of reimburse-
ment. Primary care practices have outpatient clinics
that can focus ononlyoneproblemper visit.Thismakes
it hard for these practices to reabsorb transplantation
survivors, who have multiple medical and often socio-
economic and psychological issues to be addressed in
the outpatient treatment milieu. In addition, this work-
force faces shortages and age distortions mimicking
those of HSCT physicians [3,40]. Private practice he-
matologists and medical oncologists also remain in
short supply [3]. Most of their compensation is accrued
from the active treatment of new cancer patients in
ambulatory care facilities. The lack of financial incen-tive, short supply, and older age demographics suggests
that private practice hematologists andmedical oncolo-
gists are also not a viable option to provide care for the
increasing number ofHSCT survivors.HSCT survivor
care is more complicated, given the intertwining trans-
plantation-related toxicities and comorbid diseases
present preceding and following transplantation.
Developing the necessary clinical acumen in
HSCT takes time. The years required to develop
expertise in clinical HSCT adds to the already in-
creased demands for both internal medicine training
and hematology/oncology training. The total training
period can now be as long as 10-12 years after under-
graduate training. Increasing the workforce supply by
the year 2020 requires changes in medical school and
postgraduate training now. Additional surveys are
needed to better understand the problems with the
BMT workforce. New Current Procedural Terminol-
ogy codes have been created to help bill for services for
which transplantation physicians could not bill previ-
ously. Billing for this requires increased documenta-
tion to capture the work effort, to ensure that HSCT
providers receive an appropriate salary for their work.
But because this billing documentation is time-
consuming, physicians often do not bill for these new
services. Recent data raise the possibility that compared
with peripheral blood progenitor cell harvest, tradi-
tional bone marrow harvest improves survival in pa-
tients undergoing allogeneic HSCT because of
a decreased risk of grade II-IV acute and chronic
GVHD [41]. If this is confirmed by more studies, this
raises the concern of possibly an inadequate number
of doctors with time to go to the operating room.
The increased clinical demands on the BMTwork-
force can be anticipated to have a negative impact on
the performance of quality clinical and basic science
research. In addition, with the increasing stress on
the BMT workforce to meet ongoing patient needs,
less time and energy will be available for teaching
and effective involvement in medical education roles.
This can become a vicious cycle, because contact
with HSCT physicians in teaching roles might other-
wise inspire medical students and residents to consider
cell therapy as a career subspecialty. Failure to make
time for teaching medical students and residents be-
fore they enter fellowships can only further exacerbate
the BMT workforce problems.
AsHSCTphysicians, we support an increase inUS
medical school enrollment and graduations. The
ASBMT must work to expand support for graduate
medical education funding, regardless of whether or
not the Medicare budget is the proper source of that
funding. We need to support an across-the-board in-
crease in funding for graduate-level internal medicine,
pediatric, and hematology/oncology medical educa-
tion. Our members must increase involvement with
their medical schools and internal medicine and
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for managing inpatients with complex multiorgan dys-
function is provided and that the field of HSCT is pre-
sented in a positive fashion. The society and medical
institutions need to reward efforts to encourage
HSCT physicians’ involvement in medical education.
We also need to assess ways to better fund training
for HSCT careers and develop programs that retain
active physicians beyond the traditional retirement
age of 65 years. This will require more creative care de-
livery systems for the long-term HSCT survivors.
Like so many specialties, HSCT physicians are on
the cusp of problems facing the health care system as
a whole. The fact that the HSCT field is a paradigm
for the problems facing themedical community at large
reflects the complexity of our patients and the large
amount of health care resources that they consume.
With primary care and other workforces taking care
of larger groups of patients, the HSCT community
cannot rely onoutside or governmental help to alleviate
the impending lack of providers. The HSCT commu-
nity and the facilities providing this care must address
this workforce shortage to ensure that our patients con-
tinue to have access to care. Only through a concerted,
prolonged effort can we ensure an adequate supply of
physicians specializing in HSCT to care for the many
new patients and survivors requiring our services.ACKNOWLEDGMENTS
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